Trial Profile
Study of dasatinib (BMS-354825) in subjects with chronic myelogenous leukemia with accelerated or myeloid or lymphoid blast phase or Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib mesylate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Dec 2007 Status changed from in progress to completed.
- 08 Aug 2006 New trial record.